Operations: The company's revenue segments include CN￥228.13 billion from Core Local Commerce and CN￥77.56 billion from New Initiatives.

Insider Ownership: 11.6%

Meituan's recent earnings report showed substantial growth, with sales reaching CNY 155.53 billion and net income doubling to CNY 16.72 billion for the first half of 2024. The company also announced a share repurchase program worth up to $1 billion, indicating confidence in its future prospects. Despite no substantial insider buying recently, Meituan's earnings are forecasted to grow significantly at 25.8% annually, outpacing the Hong Kong market average of 11.7%.

• Click to explore a detailed breakdown of our findings in Meituan's earnings growth report.

• Our expertly prepared valuation report Meituan implies its share price may be lower than expected.

Akeso

Simply Wall St Growth Rating: ★★★★★★

Overview: Akeso, Inc., a biopharmaceutical company with a market cap of HK$48.31 billion, researches, develops, manufactures, and commercializes antibody drugs.

Operations: Revenue from the research, development, production, and sale of biopharmaceutical products amounts to CN￥1.87 billion.

Insider Ownership: 20.5%

Akeso, a growth company with high insider ownership in Hong Kong, is forecasted to achieve significant revenue growth of 32.7% annually and become profitable within three years. Despite recent dilution and a half-year net loss of CNY 238.59 million, the company's innovative drug pipeline shows promise. Ivonescimab's recent approvals and ongoing clinical trials highlight its potential impact on cancer treatment, positioning Akeso for substantial future growth.

• Delve into the full analysis future growth report here for a deeper understanding of Akeso.

• According our valuation report, there's an indication that Akeso's share price might be on the expensive side.

Next Steps

• Explore the 47 names from our Fast Growing SEHK Companies With High Insider Ownership screener here.

• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.

• Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include SEHK:1821 SEHK:3690 and SEHK:9926.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]